SELECTED FINANCIAL STATEMENT INFORMATION (Tables)

6 Months Ended

Apr. 30, 2016

Selected Financial Statement Information [Abstract]

Schedule of Accounts Receivable [Table Text Block]

Accounts Receivable

(in thousands)	April 30, 2016			October 31, 2015
Accounts receivable		$182,499			$183,631
Less: Allowance for doubtful accounts	(3,292		)	(2,038		)
Accounts receivable, net		$179,207			$181,593

Schedule of Costs in Excess of Billings and Billings in Excess of Costs [Table Text Block]

Costs and Estimated Earnings on Uncompleted Percentage-of-Completion Contracts

(in thousands)	April 30, 2016			October 31, 2015
Costs incurred on uncompleted contracts		$31,256			$22,645
Estimated earnings	21,423			16,116
	52,679			38,761
Less: Billings to date	(44,993		)	(36,442		)
		$7,686			$2,319
Included in the accompanying Condensed Consolidated Balance Sheets under the following captions:
Accounts receivable, net (costs and estimated earnings in excess of billings)		$11,081			$6,263
Accrued expenses and other current liabilities (billings in excess of costs and estimated earnings)	(3,395		)	(3,944		)
		$7,686			$2,319

Schedule of Inventories [Table Text Block]

Inventories

(in thousands)	April 30, 2016			October 31, 2015
Finished products		$126,332			$119,262
Work in process	37,942			32,201
Materials, parts, assemblies and supplies	114,730			89,739
Contracts in process	4,214			4,521
Less: Billings to date	(1,078		)	(2,206		)
Inventories, net of valuation reserves		$282,140			$243,517

Schedule of Property, Plant and Equipment [Table Text Block]

Property, Plant and Equipment

(in thousands)	April 30, 2016			October 31, 2015
Land		$5,103			$5,060
Buildings and improvements	75,820			70,626
Machinery, equipment and tooling	165,211			152,022
Construction in progress	8,797			4,668
	254,931			232,376
Less: Accumulated depreciation and amortization	(137,268		)	(126,706		)
Property, plant and equipment, net		$117,663			$105,670

Schedule of Research and Development Expenses [Table Text Block]

The amount of new product research and development ("R&D") expenses included in cost of sales for the six and three months ended April 30, 2016 and 2015 is as follows (in thousands):

	Six months ended April 30,				Three months ended April 30,
	2016		2015		2016		2015
R&D expenses		$19,992		$19,439		$10,985		$10,137

Schedule of Redeemable Noncontrolling Interests [Table Text Block]

Management's estimate of the aggregate Redemption Amount of all Put Rights that the Company could be required to pay is as follows (in thousands):

	April 30, 2016		October 31, 2015
Redeemable at fair value		$74,027		$76,929
Redeemable based on a multiple of future earnings	14,353		14,353
Redeemable noncontrolling interests		$88,380		$91,282

Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]

Changes in the components of accumulated other comprehensive loss for the six months ended April 30, 2016 are as follows (in thousands):

	Foreign Currency Translation			Pension Benefit Obligation			Accumulated Other Comprehensive Loss
Balances as of October 31, 2015		($24,368	)		($712	)		($25,080	)
Unrealized gain	5,994			—			5,994
Balances as of April 30, 2016		($18,374	)		($712	)		($19,086	)